FDA: Reviewing controversial device OK

The FDA said it will re-examine its decision to approve a knee-surgery device last December over the objections of several scientists and managers at the agency, according to a letter from the agency that the Senate Finance Committee reviewed Monday. Report

Suggested Articles

Pfizer
Marketing

Pfizer's Xeljanz gets EMA blood clots warning

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

by Angus Liu
Antibiotic-resistant bacteria
Pharma

FDA approves Shionogi's Fetroja with scary mortality warning

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

by Kyle Blankenship
Asia Map
Pharma Asia

Sandoz, Lupin, Dr. Reddy's, Aslan and more—FiercePharmaAsia

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

by Angus Liu